Additional analysis of gene polymolphisms in the phase II study of erlotinib in previously treated advanced non-small cell lung cancer patients with carcinomatous meningitis (UMIN000007020)

Additional analysis of gene polymolphisms in the phase II study of erlotinib in previously treated advanced non-small cell lung cancer patients with carcinomatous meningitis (UMIN000007020) - Additional analysis of gene polymorphisms in phase II study of erlotinib for carcinomatous meningitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012622

Enrollment

Registered

2013-12-19

Start date

2013-09-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients enrolled onto the phase II study of erlotinib for carcinomatous meningitis who had available blood sample after 4 weeks treatment.

Exclusion criteria

Exclusion criteria: Nothing particular

Design outcomes

Primary

Measure	Time frame
Gene polymorphisms analysis	—

Countries

Japan

Contacts

Public ContactKaname Nosaki

National Kyushu Cancer Center Department of Thoracic Oncology

nosaki.k@nk-cc.go.jp092-541-3231

Outcome results